Technical Analysis for ADMP - Adamis Pharmaceuticals Corporation

Grade Last Price % Change Price Change
grade D 0.87 0.27% 0.00
ADMP closed up 0.27 percent on Monday, November 18, 2019, on 75 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Up Down
See historical ADMP trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.27%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.27%
Spinning Top Other 0.27%
Calm After Storm Range Contraction 0.27%
Narrow Range Bar Range Contraction 0.27%
NR7 Range Contraction 0.27%

Older signals for ADMP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adamis Pharmaceuticals Corporation, a biopharmaceutical company, engages in the development and commercialization of specialty pharmaceutical products in the therapeutic areas of oncology, immunology and infectious diseases, and allergy and respiratory. The company focuses on the development of small molecule compounds, which comprise APC-100, APC-200, and APC-300 for the treatment of human prostate cancer; telomerase vaccine technologies; and other vaccine technologies for providing protection against various viral infectious agents. Its products under development also comprise TeloB-VAX, a novel cell-based vaccine product for prostate cancer; and Savvy(C31G), a contraceptive gel. The company's allergy and respiratory product pipeline includes Epinephrine Injection USP 1, a pre-filled single dose syringe product for use in the emergency treatment of extreme acute allergic reactions or anaphylactic shock; APC-1000, a steroid hydrofluoroalkane (HFA) metered dose inhaler product for asthma and chronic obstructive pulmonary disease; APC-2000, a generic HFA bronchodilator; and APC-3000, an HFA pressurized metered dose nasal steroid for the treatment of seasonal and perennial allergic rhinitis. It has a strategic manufacturing, supply, and product development agreement with Beximco Pharmaceuticals Ltd. The company is based in San Diego, California.
Medicine Biopharmaceutical Health Manufacturing Medical Specialties Infectious Diseases Pharmaceutical Products Prostate Cancer Respiratory Therapy Asthma Allergy Dosage Forms Chronic Obstructive Pulmonary Disease Smoking Cessation Emergency Treatment Inhaler Metered Dose Inhaler Rhinitis
Is ADMP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 2 bullish, 2 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 3.29
52 Week Low 0.48
Average Volume 1,631,894
200-Day Moving Average 1.5278
50-Day Moving Average 0.7381
20-Day Moving Average 0.8156
10-Day Moving Average 0.9137
Average True Range 0.1133
ADX 31.6
+DI 25.8603
-DI 20.6164
Chandelier Exit (Long, 3 ATRs ) 0.7401
Chandelier Exit (Short, 3 ATRs ) 0.8405
Upper Bollinger Band 1.0516
Lower Bollinger Band 0.5796
Percent B (%b) 0.62
BandWidth 57.871506
MACD Line 0.0601
MACD Signal Line 0.0531
MACD Histogram 0.007
Fundamentals Value
Market Cap 27.28 Million
Num Shares 31.4 Million
EPS -0.87
Price-to-Earnings (P/E) Ratio -1.00
Price-to-Sales 14.86
Price-to-Book 4.42
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.02
Resistance 3 (R3) 1.01 0.96 1.00
Resistance 2 (R2) 0.96 0.92 0.96 0.99
Resistance 1 (R1) 0.91 0.89 0.92 0.92 0.98
Pivot Point 0.86 0.86 0.86 0.86 0.86
Support 1 (S1) 0.81 0.82 0.82 0.82 0.76
Support 2 (S2) 0.76 0.79 0.76 0.75
Support 3 (S3) 0.71 0.76 0.75
Support 4 (S4) 0.72